acute decompensated heart failure
Conditions
Interventions
Experimental group (sacubitril/valsartan) and control group (ACRI or ARB):sacubitril/valsartan
Sponsors
Department of Cardiology, The First Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Eligibility requirements included an age of 18 years or older, NYHA class III - IV, and an ejection fraction of 40% or less. Patients were required to have a B-type natriuretic peptide (BNP) level >=400 pg per milliliter or an N-terminal pro-BNP (NT-proBNP) level >=1600 pg per milliliter, a systolic blood pressure at least 100 mmHg, an estimated glomerular filtration rate (eGFR) >=30 mL/min per 1.73 m2 (calculated by the Modification of Diet in Renal Disease formula), and a potassium concentration =100 mm Hg with no need for intravenous diuretics during the prior 24 hours.
Exclusion criteria
Exclusion criteria: With a history of angioedema or other unacceptable side effects of ACEI or ARB, an allergy history of any ingredient of sacubitril/valsartan, occurrence of acute myocardial infarction in the previous month, being in perinatal period, presence of diseases that may seriously affect drug metabolism, or the patient's life expectancy less than 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| death from any cause; | — |
Secondary
| Measure | Time frame |
|---|---|
| the readmission for HF;NYHA grade; 6-minute walk distance; | — |
Countries
China
Contacts
Public ContactWeimin Li
Department of Cardiology, The First Affiliated Hospital of Harbin Medical University
Outcome results
None listed